These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15298580)

  • 1. Cost-effectiveness of cognitive behavioural therapy and selective serotonin reuptake inhibitors for major depression in children and adolescents.
    Haby MM; Tonge B; Littlefield L; Carter R; Vos T
    Aust N Z J Psychiatry; 2004 Aug; 38(8):579-91. PubMed ID: 15298580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.
    Heuzenroeder L; Donnelly M; Haby MM; Mihalopoulos C; Rossell R; Carter R; Andrews G; Vos T
    Aust N Z J Psychiatry; 2004 Aug; 38(8):602-12. PubMed ID: 15298582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behavioural therapy in adolescents with major depression.
    Byford S; Barrett B; Roberts C; Wilkinson P; Dubicka B; Kelvin RG; White L; Ford C; Breen S; Goodyer I
    Br J Psychiatry; 2007 Dec; 191():521-7. PubMed ID: 18055956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is implementation of the 2013 Australian treatment guidelines for posttraumatic stress disorder cost-effective compared to current practice? A cost-utility analysis using QALYs and DALYs.
    Mihalopoulos C; Magnus A; Lal A; Dell L; Forbes D; Phelps A
    Aust N Z J Psychiatry; 2015 Apr; 49(4):360-76. PubMed ID: 25348698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression.
    Vos T; Corry J; Haby MM; Carter R; Andrews G
    Aust N Z J Psychiatry; 2005 Aug; 39(8):683-92. PubMed ID: 16050922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings.
    Lynch FL; Dickerson JF; Clarke G; Vitiello B; Porta G; Wagner KD; Emslie G; Asarnow JR; Keller MB; Birmaher B; Ryan ND; Kennard B; Mayes T; DeBar L; McCracken JT; Strober M; Suddath RL; Spirito A; Onorato M; Zelazny J; Iyengar S; Brent D
    Arch Gen Psychiatry; 2011 Mar; 68(3):253-62. PubMed ID: 21383263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder.
    Donnelly M; Haby MM; Carter R; Andrews G; Vos T
    Aust N Z J Psychiatry; 2004 Aug; 38(8):592-601. PubMed ID: 15298581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive-behavioural therapy and short-term psychoanalytic psychotherapy versus brief psychosocial intervention in adolescents with unipolar major depression (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled trial.
    Goodyer IM; Reynolds S; Barrett B; Byford S; Dubicka B; Hill J; Holland F; Kelvin R; Midgley N; Roberts C; Senior R; Target M; Widmer B; Wilkinson P; Fonagy P
    Health Technol Assess; 2017 Mar; 21(12):1-94. PubMed ID: 28394249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women.
    Revicki DA; Siddique J; Frank L; Chung JY; Green BL; Krupnick J; Prasad M; Miranda J
    Arch Gen Psychiatry; 2005 Aug; 62(8):868-75. PubMed ID: 16061764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults.
    Skapinakis P; Caldwell D; Hollingworth W; Bryden P; Fineberg N; Salkovskis P; Welton N; Baxter H; Kessler D; Churchill R; Lewis G
    Health Technol Assess; 2016 Jun; 20(43):1-392. PubMed ID: 27306503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
    Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blended vs. face-to-face cognitive behavioural treatment for major depression in specialized mental health care: study protocol of a randomized controlled cost-effectiveness trial.
    Kooistra LC; Wiersma JE; Ruwaard J; van Oppen P; Smit F; Lokkerbol J; Cuijpers P; Riper H
    BMC Psychiatry; 2014 Oct; 14():290. PubMed ID: 25326035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost and Outcome of BehaviouRal Activation (COBRA): a randomised controlled trial of behavioural activation versus cognitive-behavioural therapy for depression.
    Richards DA; Rhodes S; Ekers D; McMillan D; Taylor RS; Byford S; Barrett B; Finning K; Ganguli P; Warren F; Farrand P; Gilbody S; Kuyken W; O'Mahen H; Watkins E; Wright K; Reed N; Fletcher E; Hollon SD; Moore L; Backhouse A; Farrow C; Garry J; Kemp D; Plummer F; Warner F; Woodhouse R
    Health Technol Assess; 2017 Aug; 21(46):1-366. PubMed ID: 28857042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cluster randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of classroom-based cognitive-behavioural therapy (CBT) in reducing symptoms of depression in high-risk adolescents.
    Stallard P; Phillips R; Montgomery AA; Spears M; Anderson R; Taylor J; Araya R; Lewis G; Ukoumunne OC; Millings A; Georgiou L; Cook E; Sayal K
    Health Technol Assess; 2013 Oct; 17(47):vii-xvii, 1-109. PubMed ID: 24172024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing Cost-Effectiveness--Mental Health: introduction to the study and methods.
    Haby MM; Carter R; Mihalopoulos C; Magnus A; Sanderson K; Andrews G; Vos T
    Aust N Z J Psychiatry; 2004 Aug; 38(8):569-78. PubMed ID: 15298579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder.
    Fineberg NA; Baldwin DS; Drummond LM; Wyatt S; Hanson J; Gopi S; Kaur S; Reid J; Marwah V; Sachdev RA; Pampaloni I; Shahper S; Varlakova Y; Mpavaenda D; Manson C; O'Leary C; Irvine K; Monji-Patel D; Shodunke A; Dyer T; Dymond A; Barton G; Wellsted D
    Int Clin Psychopharmacol; 2018 Nov; 33(6):334-348. PubMed ID: 30113928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services.
    Vos T; Haby MM; Magnus A; Mihalopoulos C; Andrews G; Carter R
    Aust N Z J Psychiatry; 2005 Aug; 39(8):701-12. PubMed ID: 16050924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2019; 19(6):1-199. PubMed ID: 30873251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
    Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
    Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.